NanoViricides scheduled to begin preclinical testing of rabies drug

By Elaine Rigoli

Tampa, Fla., Aug. 10 - NanoViricides, Inc. announced that its latest drug, RabiCide-I, an anti-rabies drug, is now scheduled to begin preclinical animal testing in Vietnam by early 2007.

Although not an important disease in the United States, rabies kills over 50,000 people per year in the subtropical regions of Asia, India and Africa, the company said in a news release.

This drug was developed at the request of the National Institute of Hygiene and Epidemiology of the Ministry of Health, Government of Vietnam.

"We believe that our drug pipeline is not only rich, robust and expanding rapidly, but that it will continue to expand for several years into the future as additional applications of nanoviricides technology continue to evolve," chief executive officer Eugene Seymour said in the release.

NanoViricides is a West Haven, Conn.-based development-stage company that is creating special-purpose nanomaterials for viral therapy.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.